| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| DeLucia David | Chief Financial Officer | C/O KYNTRA BIO INC., 350 BAY STREET, SUITE 100 # 6009, SAN FRANCISCO | /s/ John Alden, Attorney-in-Fact | 05 Feb 2026 | 0002040705 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | KYNB | Stock Option (Right to Buy) | Award | $0 | +26,000 | $0.000000 | 26,000 | 03 Feb 2026 | Common Stock | 26,000 | $8.50 | Direct | F1 |
| Id | Content |
|---|---|
| F1 | The option vests in equal amount quarterly over 4 years measured from 2/3/2026. |